Meda predicts these will add upwards of $23 million in sales for the remainder of 2007.

Meda purchased 10 European on-market drugs from Wyeth for SEK 525 million, or approximately $76.49 million.

Meda expects the products to add about SEK 160-170 million, or between $23 million and $25.41 million, in sales into its operation for the rest of 2007. It reports that the acquisition enhances its position in two of its most important markets, Italy and France. These countries account for about 60% of the acquired products’ sales, according to the company.

Meda states that the biggest product acquired through this deal is Seresta®, an anti-anxiety agent used for sleep disorders and various substance-withdrawal syndromes.

Previous articleBristol-Myers Squibb and Pfizer Partner on Two Multimillion-Dollar Projects
Next articleArQule Hands Over Asian Rights to Anticancer Drug for $123M